Danaher Corp Earnings - Q2 2026 Analysis & Highlights

Danaher Corporation reported solid second quarter 2026 results with accelerating core growth, strong cash flow generation, and strategic acquisitions that position the company for continued momentum across its life sciences and diagnostics portfolios, while managing near-term bioprocessing timing challenges and navigating a stabilizing macroeconomic environment.

Key Financial Results

  • Second quarter sales reached $6.3 billion with core revenue growth of 3% year-over-year, and core growth excluding respiratory testing revenue increased 4.5%, representing a 150 basis point acceleration from the first quarter.
  • Adjusted diluted net earnings per common share of $1.94 were up approximately 8% year-over-year.
  • Gross profit margin for the second quarter was 57.6%.
  • Adjusted operating profit margin of 27.1% was down 20 basis points as lower respiratory revenue year-over-year more than offset favorable impacts of higher non-respiratory volume and disciplined cost management.
  • Free cash flow of $1.3 billion was generated in the quarter and $2.4 billion in the first half of the year, resulting in a year-to-date free cash flow to net income conversion ratio of 124%.

    • Business Segment Results

  • Biotechnology segment core revenue increased 2.5% with discovery and medical growing mid-single digits and bioprocessing growing low single digits in both consumables and equipment.
  • Bioprocessing equipment growth returned in the second quarter following several quarters of improving order trends supported by customer investments in manufacturing capacity.
  • Bioprocessing consumables growth came in below expectations as a few large shipments for programs at commercial customers moved out of the quarter, though underlying demand remained very healthy with mid-teens order growth in both consumables and equipment.
  • Life Sciences segment core revenue increased 5.5% with Pall's applied filtration business increasing approximately 10%, led by strength in its microelectronics product line.
  • Life sciences instrument businesses increased mid-single digits with solid growth at Beckman Life Sciences, Leica Microsystems, and SCIEX.
  • Life sciences consumables businesses collectively grew low single digits with IDT up led by demand for MRD testing solutions, and Abcam delivering its best quarter since acquisition.
  • Diagnostics segment core revenue increased 2% with core growth excluding respiratory testing revenue up 5%.
  • Clinical diagnostics businesses were up mid-single digits with Leica Biosystems and Radiometer collectively up high single digits and Beckman Coulter Diagnostics up mid-single digits globally.
  • Cepheid's core non-respiratory revenue increased low double digits, led by growth in hospital-acquired infection and sexual health assays.

    • Capital Allocation

  • Masimo acquisition closed in early June, ahead of initial expectations, with the business delivering high-single-digit revenue growth in the first half of the year and expected to be immediately accretive both strategically and to adjusted EPS.
  • Leica Biosystems announced the pending acquisition of StatLab, a leading manufacturer of consumables across the anatomical pathology workflow, with StatLab generating approximately $250 million in revenue for the full year of 2025 and having more than 85% recurring revenue.
  • Approximately $900 million of capital was deployed to repurchase 5 million shares of Danaher common stock.

    • Industry Trends and Dynamics

  • Demand from large pharma and biopharma customers remained healthy, while improved biotech funding supported improved funnel and order activity.
  • Academic and government markets have largely stabilized, while clinical and applied remained consistent sources of strength across the portfolio.
  • Core revenues in high growth markets increased more than 10% with healthy growth across major regions including mid-single-digit growth in China.
  • In China, biotechnology delivered another quarter of solid growth, as local companies continued to partner with Cytiva on the development of novel molecules and the manufacturing of commercial therapy.
  • Life sciences market conditions continued to stabilize while diagnostics improved sequentially, as the company began to move beyond the most significant year-over-year impact of volume-based procurement and reimbursement changes that began in late 2024.
  • Biotech demand benefited from a more favorable funding environment with better biotech funding starting to read through in the second quarter.

    • Competitive Landscape

  • Cytiva launched the Biacore 8S SPR system, a high-throughput screening and characterization platform that helps researchers evaluate how potential drug candidates interact with their targets by combining rapid screening with high-quality molecular characterization and AI-powered data analysis.
  • SCIEX reinforced its leadership position in mass spectrometry with the introduction of the novus V55, an AI-enabled triple quadrupole system that delivers enhanced sensitivity, high throughput, and helps reduce operating costs.
  • Beckman Coulter introduced the Access brain-derived pTau217 research-use-only assay and received CE mark approval for the Access pTau217 assay, further strengthening Beckman's positioning as a leader in neurodegenerative diagnostics.
  • Beckman Life Sciences saw notable growth in automation, where the team is well positioned to benefit as customers invest in the lab infrastructure needed to support autonomous labs and AI-enabled drug discovery.
  • Abcam benefited from improved commercial execution and is taking share while making headway in other end markets to diversify away from academic.

    • Macroeconomic Environment

  • Geographically, core revenues in developed markets declined slightly as both North America and Western Europe were impacted by shipment timing in biotechnology and lower respiratory revenue year-over-year.
  • At Beckman, declines in China began to moderate as pricing stabilized and volumes improved.
  • Academic demand improved modestly as the quarter progressed, but remained below normal level.
  • Academic funding area is related to government policies, and the company needs to see more constructive perspectives on academic funding before calling an inflection point.

    • Growth Opportunities and Strategies

  • The Danaher Business System and the company's team are powerful differentiators, helping drive both growth and productivity.
  • Masimo team has already completed their first operating review where they further validated opportunities to drive productivity and efficiency improvement, capture customer account synergies and strengthen the innovation process using the Danaher Business System Launch Excellence tool.
  • StatLab acquisition will strengthen Leica Biosystems' value proposition by bringing together consumables, instruments, automation, and digital pathology into a more complete workflow solution and supports the broader integrated delivery network strategy.
  • Cytiva is well positioned to support capacity expansion as the company expects onshoring activity to accelerate and commercial production to remain robust, particularly in monoclonal antibodies.
  • New molecules continue to progress through development pipelines and into commercialization, creating a durable long-term growth opportunity given Cytiva's leading and expanding specced-in position on molecules in preclinical and early stage clinical development phases.
  • As end market conditions continue to improve, commercial and go-to-market execution, including autonomous lab catalyzed demand, is expected to further support growth acceleration across Abcam, IDT and Aldevron.
  • The company is starting to see green shoots around the AI dynamic with increased demand across the portfolio, including at Beckman, for increased automation for lab in a loop or autonomous science applications.
  • The company believes AI will strengthen the Danaher Business System, reinforcing the culture of continuous improvement and supporting work to achieve margin expansion and earnings growth.

    • Financial Guidance and Outlook

  • Third-quarter revenue growth is expected to be approximately 2% to 3%, which includes an approximately 250 basis point year-over-year headwind from respiratory testing, implying core growth excluding respiratory of approximately 5%.
  • The company continues to expect to exit Q4 at the mid-single-digit core revenue growth rate, as it moves past some of the headwinds from the first three quarters of the year.
  • Full-year 2026 core revenue growth outlook is in the range of 3% to 4%.
  • Updated outlook reflects higher anticipated core revenue growth in the life sciences segment, as these markets are expected to recover faster than initial expectations, offset by a slightly more conservative outlook for bioprocessing.
  • Full year adjusted diluted net EPS guidance has been raised to a range of $8.45 to $8.60 versus the previous range of $8.35 to $8.55.
  • Third quarter adjusted operating profit margin is expected to be approximately 26.5%.
  • StatLab is expected to grow high single digits over the long term and to be accretive to adjusted EPS in the first full year of ownership, with the transaction expected to close by the end of 2026.
  • Bioprocessing is expected to maintain a high-single-digit long-term outlook, supported by capacity expansion and commercial production remaining robust, particularly in monoclonal antibodies.
  • Leica Biosystems and Radiometer are solidly into the high single digits and the company believes that continues for the long term.
  • Respiratory revenue is expected to be approximately $1.6 billion or a touch below that for the full year.
  • The company expects growth to accelerate toward a mid-single-digit exit rate this year as markets recover and growth initiatives gain further traction.